SEC 13F Intelligence

Managers / Q1 2022 · view latest →

M28 Capital Management LP

CIK 0001807489 · 700 CANAL STREET, 1ST FLOOR, STAMFORD, CT, 06902 · 203-516-3730

Reported Value
$109M
Q1 2022
Positions
13
Filings on Record
18
2019–present window
Filed
May 13, 2022
original filing

Summary

M28 Capital Management LP reported $109M in U.S.-listed holdings across 13 positions for Q1 2022.

The portfolio is heavily concentrated: IVVD alone accounts for 26.8% of reported value.

Compared with Q4 2021, the fund opened 2 new positions and exited 1.

Portfolio Metrics

Turnover
+9.2%
vs prior filed quarter
Top-10 Concentration
+95.3%
share of reported value
Largest Position
+26.8%
Adagio Therapeutics
New / Exited
2 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’21: $128MQ4 ’21Q1 ’22: $109MQ2 ’22: $89MQ3 ’22: $96MQ3 ’22Q4 ’22: $105MQ1 ’23: $88MQ2 ’23: $76MQ2 ’23Q3 ’23: $87MQ4 ’23: $121MQ1 ’24: $135MQ1 ’24Q2 ’24: $77MQ3 ’24: $91MQ4 ’24: $102MQ4 ’24Q1 ’25: $73MQ2 ’25: $59MQ3 ’25: $68MQ3 ’25Q4 ’25: $138MQ1 ’26: $54Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 75.4%Other: 24.6%
  • Common Stock · 75.4% · $82M
  • Other · 24.6% · $27M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VERVE THERAPEUTICS INCNEW+178.5K178.5K+$4M$4M
PROQR THERAPEUTICS N VNEW+1.00M1.00M+$907,000$907,000
MRTXEURMIRATI THERAPEUTICS INCADDED+63.7K82.9K+$4M$7M
LEAP THERAPEUTICS INCADDED+1.66M2.66M+$1M$5M
NKTREURNEKTAR THERAPEUTICSSOLD OUT−560.6K0−$8M$0
TGTXTG THERAPEUTICS INCADDED+520.9K1.05M−$47,000$10M
CURIS INCADDED+1.63M4.24M−$2M$10M
WAVE LIFE SCIENCES LTDADDED+2.08M5.85M−$124,000$12M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

13 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1IVVDADAGIO THERAPEUTICS INChistory →COM26.83%$29M6.40M
2WAVE LIFE SCIENCES LTDSHS10.76%$12M5.85M
3RCKTROCKET PHARMACEUTICALS INChistory →COM10.44%$11M715.9K
4STOKSTOKE THERAPEUTICS INChistory →COM10.20%$11M527.1K
5CURIS INCCOM NEW9.29%$10M4.24M
6TGTXTG THERAPEUTICS INChistory →COM9.16%$10M1.05M
7MRTXEURMIRATI THERAPEUTICS INChistory →COM6.27%$7M82.9K
8BBIOBRIDGEBIO PHARMA INChistory →COM4.35%$5M466.2K
9LEAP THERAPEUTICS INCCOM4.29%$5M2.66M
10VERVE THERAPEUTICS INCCOM3.74%$4M178.5K
11ATRAGBXATARA BIOTHERAPEUTICS INChistory →COM3.33%$4M389.4K
12PROQR THERAPEUTICS N VSHS EURO0.83%$907,0001.00M
13NEXI1EURNEXIMMUNE INCCOM0.52%$562,000133.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$54M9May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$138M9Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$68M9Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$59M9Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$73M11May 14, 202513F-HRchanges · EDGAR ↗
Q4 2024$102M11Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$91M11Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$77M11Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$135M11May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$121M10Feb 12, 202413F-HRchanges · EDGAR ↗
Q3 2023$87M11Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$76M12Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$88M14May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M14Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$96M12Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$89M13Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$109M13May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$128M12Feb 11, 202213F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.